{"contentid": 488235, "importid": NaN, "name": "Hemogenyx updates on CDX antibody development", "introduction": "UK-based biopharma firm Hemogenyx Pharmaceuticals has issued an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody (CDX) for the treatment of acute myeloid leukemia (AML).", "content": "<p>UK-based biopharma firm Hemogenyx Pharmaceuticals (LSE: HEMO) has issued an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody (CDX) for the treatment of acute myeloid leukemia (AML).</p>\n<p>On January 13, 2021, the company <a href=\"https://hemogenyx.com/investors/investors/announcements/announcement/2021/update-on-cdx-antibody-development/\">announced</a> the completion of development of CDX with an unnamed pharmaceutical company (dubbed \"GlobalCo\"). With the development phase of the agreement completed, GlobalCo may exercise an option to license the other party's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis, said Hemogenyx, whose shares were down 1.8% at 6.92 pence by mid-afternoon trading today.</p>\n<p>Hemogenyx also announced that negotiations have commenced with GlobalCo regarding the form of licensing and further development of CDX toward clinical trials. The results of these negotiations and the outline of the path toward the further development of CDX will be announced upon their completion.</p>\n<p>At the same time, the company is progressing in the development of its leading product candidate chimeric antigen receptor (CAR) T-cells (HEMO-CAR-T). As announced on <a href=\"https://hemogenyx.com/investors/investors/announcements/announcement/2021/hemo-car-t-update/\">3 March 2021</a>, the company has engaged a highly experienced consultant in the field of manufacturing and quality control operations and has initiated the process of engaging contract manufacturing organizations (CMOs) for product development and manufacturing to support Phase I clinical trials of HEMO-CAR-T.</p>\n<p>Discussions and negotiations with CMOs continue and the directors are confident that the company is poised to move ahead toward clinical trials with an outstanding team, including the University of Pennsylvania, with which the company has entered into a Master Translation research service agreement, the goal of which is to advance HEMO-CAR-T toward clinical trials.</p>\n<p>&ldquo;We are pleased with the continued interest of GlobalCo in facilitating the advancement of the CDX antibody toward the clinic, having concluded the highly successful development phase of this product candidate. We are also excited about the progress being made in moving HEMO-CAR-T toward clinical trials. Having two lead product candidates that have resulted in collaborations with such esteemed organizations and both moving toward clinical trials is testament to the company's exceptional team of scientists and our dedication to cutting edge science,\" commented Dr Vladislav Sandler, chief executive and co-founder of Hemogenyx.</p>", "date": "2021-04-01 14:58:00", "meta_title": "Hemogenyx updates on CDX antibody development", "meta_keywords": "Hemogenyx Pharmaceuticals, Updates, CDX antibody, Leukemia, Myeloid, Negotiations", "meta_description": "Hemogenyx updates on CDX antibody development", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 14:57:10", "updated": "2021-04-01 15:06:32", "access": NaN, "url": "https://www.thepharmaletter.com/article/hemogenyx-updates-on-cdx-antibody-development", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "hemogenyx_big.png", "image2id": "hemogenyx_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Deals, Licensing, One to Watch Companies, Research", "geography_tag": "UK", "company_tag": "CDX, HemoGenyx Pharmaceuticals", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 14:58:00"}